Pfizer Stuns Observers With Negative Growth In Emerging Markets In Q411

BMI View: Investor perception of Pfizer during 2012 will be dominated by four key factors: the successful divestment of its non-core nutritional and animal health assets, whether the company can reverse its underperformance in emerging markets, the extent of share repurchases and pipeline progression. Pfizer's renewed appreciation of health technology assessment underlines our favourable opinion of the world's largest pharmaceutical company, which is changing from a primary care to a specialty

To read the full article, please choose one of the following options: